We found that pyrimidine metabolic rate–limiting enzymes CAD, CTPS, DTYMK, RRM1, RRM2, TYMS, UCK2, and TK1 were all highly expressed in TP53 mutant lung cancer patients (Fig. 8b). This evidence concerns the gene RRM2 and lung carcinoma.